These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 31997959)
1. The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Leucht S; Rossum IW; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE Focus (Am Psychiatr Publ); 2016 Jul; 14(3):378-386. PubMed ID: 31997959 [TBL] [Abstract][Full Text] [Related]
2. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Smith RC; Leucht S; Davis JM Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237 [TBL] [Abstract][Full Text] [Related]
3. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Fleischhacker WW; Keet IP; Kahn RS; Schizophr Res; 2005 Oct; 78(2-3):147-56. PubMed ID: 16055308 [TBL] [Abstract][Full Text] [Related]
4. Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand. Boonlue T; Subongkot S; Dilokthornsakul P; Kongsakon R; Pattanaprateep O; Suanchang O; Chaiyakunapruk N Clinicoecon Outcomes Res; 2016; 8():127-36. PubMed ID: 27199568 [TBL] [Abstract][Full Text] [Related]
5. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710 [TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. Huhn M; Nikolakopoulou A; Schneider-Thoma J; Krause M; Samara M; Peter N; Arndt T; Bäckers L; Rothe P; Cipriani A; Davis J; Salanti G; Leucht S Focus (Am Psychiatr Publ); 2020 Oct; 18(4):443-455. PubMed ID: 33343258 [TBL] [Abstract][Full Text] [Related]
7. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy. Hatta K; Sugiyama N; Ito H Ther Adv Psychopharmacol; 2018 Jun; 8(6):173-183. PubMed ID: 29854396 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Foussias G; Remington G Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961 [TBL] [Abstract][Full Text] [Related]
9. Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results. Chen L; McCombs JS; Park J Value Health; 2008; 11(3):487-96. PubMed ID: 18489672 [TBL] [Abstract][Full Text] [Related]
10. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Park S; Ross-Degnan D; Adams AS; Sabin J; Kanavos P; Soumerai SB Br J Psychiatry; 2005 Aug; 187():137-42. PubMed ID: 16055824 [TBL] [Abstract][Full Text] [Related]
11. Strategies for dosing and switching antipsychotics for optimal clinical management. Buckley PF; Correll CU J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
13. [Switching to monotherapy and optimization of drug therapy for long-term hospitalized patients and chronically sick patients]. Hirao T Seishin Shinkeigaku Zasshi; 2011; 113(10):1041-7. PubMed ID: 22187892 [TBL] [Abstract][Full Text] [Related]
14. Original research paper. Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. Bole CB; Pišlar M; Šen M; Tavčar R; Mrhar A Acta Pharm; 2017 Mar; 67(1):99-112. PubMed ID: 28231044 [TBL] [Abstract][Full Text] [Related]
15. The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder. Ko YH; Na KS; Kim CE; Kim SH; Jeon YW; Yi JS; Lee MS; Kim SG; Jeong HG; Jung HY Psychiatry Investig; 2014 Oct; 11(4):459-66. PubMed ID: 25395978 [TBL] [Abstract][Full Text] [Related]
16. Herbert C. Moffitt, Sr: Reprinted, by permission, from The Bulletin, San Francisco Medical Society, March, 1951. Bruck EL Calif Med; 1951 Apr; 74(4):280-1. PubMed ID: 18731748 [No Abstract] [Full Text] [Related]
17. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748 [TBL] [Abstract][Full Text] [Related]
18. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Marteene W; Winckel K; Hollingworth S; Kisely S; Gallagher E; Hahn M; Ebdrup BH; Firth J; Siskind D Expert Opin Drug Saf; 2019 Dec; 18(12):1149-1160. PubMed ID: 31564170 [No Abstract] [Full Text] [Related]
19. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia. Wisniewski CS; Robert S Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346 [TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J; Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]